SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

Scientists reveal that reactivation of Epstein-Barr virus (EBV), driven by TGFβ-induced immune suppression, is a key driver ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

China on Thursday urged caution and political restraint in the wake of reports that Germany's BND intelligence agency ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close contact with someone who is infected vulnerable to developing COVID ...

Several studies have suggested that COVID-19 may increase a person’s risk of developing cancer or promote metastasis of existing cancer.

The following is a summary of “Association between SARS-CoV-2 and stroke: perspectives from a metaumbrella-review,” published in the March 2025 issue of BMC Neurology by Baldo de Souza et al. The ...

PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1, XEC, and LP.8.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding ...

Monoclonal antibodies like etesevimab have lost efficacy against Omicron subvariants, necessitating innovative solutions.